tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Lung Diseases D008171 37 associated lipids
Nervous System Diseases D009422 37 associated lipids
Heart Failure D006333 36 associated lipids
Glomerulonephritis D005921 35 associated lipids
Acne Vulgaris D000152 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Burns D002056 34 associated lipids
Cataract D002386 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Uremia D014511 33 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Memory Disorders D008569 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Stroke D020521 32 associated lipids
Diarrhea D003967 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Liver Diseases D008107 31 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Catalepsy D002375 30 associated lipids
Kidney Diseases D007674 29 associated lipids
Obesity D009765 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Cholestasis D002779 23 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Fibrosis D005355 23 associated lipids
Cystitis D003556 23 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Hypersensitivity D006967 22 associated lipids
Erythema D004890 22 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sampson BA and Gotschlich EC Neisseria meningitidis encodes an FK506-inhibitable rotamase. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1371354
Andersson J et al. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. 1992 Immunology pmid:1371491
Strasser S et al. Effect of FK506 on insulin secretion in normal dogs. 1992 Metab. Clin. Exp. pmid:1371575
Taormina D et al. Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. 1992 Am J Hosp Pharm pmid:1373936
Ochiai T [Advances in the fundamentals and therapeutic use of immunosuppressive agents]. 1992 Arerugi pmid:1374229
Hung DT and Schreiber SL cDNA cloning of a human 25 kDa FK506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1374240
Jayaraman T et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). 1992 J. Biol. Chem. pmid:1374404
Graeb C et al. Cytoimmunologic monitoring of small bowel allograft recipients. 1992 Transplant. Proc. pmid:1376515
Date K et al. Effect of FK 506 on graft survival in rat small intestinal allografts. 1992 Transplant. Proc. pmid:1376516
Hatazawa C et al. Effect of FK 506 on bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376517
Moutabarrik A et al. FK506-induced kidney tubular cell injury. 1992 Transplantation pmid:1281562
Yagihashi A et al. HLA matching effect in liver transplantation. 1992 Transplant. Proc. pmid:1281569
Kobayashi M et al. Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. 1992 Transplant. Proc. pmid:1281570
Ramamoorthy S et al. Selective impairment of taurine transport by cyclosporin A in a human placental cell line. 1992 Pediatr. Res. pmid:1378960
Armitage JM et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. 1992 Ann. Thorac. Surg. pmid:1379032
Thomson AW The spectrum of action of new immunosuppressive drugs. 1992 Clin. Exp. Immunol. pmid:1379130
Fischer G et al. Mip protein of Legionella pneumophila exhibits peptidyl-prolyl-cis/trans isomerase (PPlase) activity. 1992 Mol. Microbiol. pmid:1379319
Bach JF Immunointervention in autoimmune diseases from cellular selectivity to autoantigen specificity. 1992 J. Autoimmun. pmid:1380245
Baumann G et al. Molecular mechanisms of immunosuppression. 1992 J. Autoimmun. pmid:1380246
Walpoth B et al. Assessment of new immunosuppressive drugs in a rat cardiac allograft heterotopic model. 1992 Eur Surg Res pmid:1380460
Ericzon BG et al. FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. 1992 Transplantation pmid:1384189
Meiser BM et al. Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. 1992 Transplant. Proc. pmid:1384201
Wakabayashi H et al. Effect of FK 506 and cyclosporine A on hepatic energy status in the rat after warm ischemia, as monitored by 31P nuclear magnetic resonance spectroscopy in vivo. 1992 Transplant. Proc. pmid:1384205
Jordan ML et al. Initial studies with FK506 in renal transplantation. 1991 Sep-Oct Cleve Clin J Med pmid:1718631
Iwasaki K et al. Pharmacokinetic study of FK 506 in the rat. 1991 Transplant. Proc. pmid:1721268
Kay JE et al. Uptake of FK 506 by lymphocytes and erythrocytes. 1991 Transplant. Proc. pmid:1721269
Jain AB et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721270
Abu-Elmagd KM et al. Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1721271
Abu-Elmagd KM et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. 1991 Transplant. Proc. pmid:1721272
Ericzon BG et al. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. 1991 Transplant. Proc. pmid:1721273
Dumont FJ et al. Up-regulation of gene expression by FK 506. 1991 Transplant. Proc. pmid:1721300
Rao P et al. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. 1991 Transplant. Proc. pmid:1721301
DiLella AG and Craig RJ Characterization of the human FKBP-12 gene and related pseudogenes. 1991 Transplant. Proc. pmid:1721302
Kar S and Carr B Gene expression of FK 506-binding protein. 1991 Transplant. Proc. pmid:1721303
Connelly PR Thermodynamics of interaction of FK 506-binding protein and its ligands. 1991 Transplant. Proc. pmid:1721304
Donnelly JG and Soldin SJ Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. 1991 Transplant. Proc. pmid:1721305
Borg AJ and Kumagai M FK 506 and xenogeneic human anti-porcine cellular reactivity. 1991 Transplant. Proc. pmid:1721332
Fung J et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. 1991 Transplant. Proc. pmid:1721333
Winkler M et al. Use of FK 506 for treatment of chronic rejection after liver transplantation. 1991 Transplant. Proc. pmid:1721334
D'Alessandro AM et al. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. 1991 Transplant. Proc. pmid:1721335
Lewis WD et al. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. 1991 Transplant. Proc. pmid:1721336
Woodle ES et al. FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. 1991 Transplant. Proc. pmid:1721337
Jensen CW et al. Pediatric renal transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721364
McCauley J et al. The question of FK 506 nephrotoxicity after liver transplantation. 1991 Transplant. Proc. pmid:1703344
Jordan ML et al. FK 506 conversion of renal allografts failing cyclosporine immunosuppression. 1991 Transplant. Proc. pmid:1721365
Alessiani M et al. Infections in adult liver transplant patients under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703345
Offner G et al. FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. 1991 Transplant. Proc. pmid:1721366
Imai K et al. Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. 1991 Transplant. Proc. pmid:1703347
Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721367
Starzl TE et al. Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. 1991 Transplant. Proc. pmid:1703351
Darras FS et al. Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721368
Shapiro R et al. Kidney transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703352
Todo S et al. Clinical small bowel or small bowel plus liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721369
Tzakis AG et al. Use of FK 506 in pediatric patients. 1991 Transplant. Proc. pmid:1703353
Freise CE et al. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. 1991 Transplant. Proc. pmid:1721397
Eidelman BH et al. Neurologic complications of FK 506. 1991 Transplant. Proc. pmid:1721398
DiMartini A et al. Psychiatric morbidity in liver transplant patients. 1991 Transplant. Proc. pmid:1721399
Lopez OL et al. Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721400
Viebahn R et al. Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721401
Steinmann B et al. Mechanism of action of FK 506 and cyclosporin. 1991 Lancet pmid:1704088
Sewing KF and Christians U FK 506. 1991 Lancet pmid:1704090
Wiederrecht G et al. FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1704127
Ziccardi VB et al. Maxillofacial considerations in orthotopic liver transplantation. 1991 Oral Surg. Oral Med. Oral Pathol. pmid:1704494
Bierer BE et al. The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. 1991 Eur. J. Immunol. pmid:1705513
Fukuzawa M et al. Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. 1991 Transplant. Proc. pmid:1721427
Ogasa N et al. Effect of FK 506 on growth of transplanted newborn rat intestine. 1991 Transplant. Proc. pmid:1721428
de Bruin RW et al. Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721429
Langrehr JM et al. FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. 1991 Transplant. Proc. pmid:1721430
Gotoh M et al. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. 1991 Transplant. Proc. pmid:1721431
Valdivia LA et al. Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721432
Neuberger J FK 506--a promise of good things to come? 1991 Hepatology pmid:1711005
Halloran PF and Madrenas J The mechanism of action of cyclosporine: a perspective for the 90's. 1991 Clin. Biochem. pmid:1711939
Palaszynski EW et al. Purification and characterization of cyclosporine and FK-506 binding proteins from a human T-helper cell line. 1991 Clin. Biochem. pmid:1711940
Shiraki K et al. Effect of FK-506 on replication of human cytomegalovirus in vitro. 1991 J. Antibiot. pmid:1712008
Sigal NH et al. Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. 1991 Transplant. Proc. pmid:1712132
Fung JJ et al. Current status of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1712133
McCauley J et al. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. 1991 Transplant. Proc. pmid:1721459
Carrieri G et al. Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. 1991 Transplant. Proc. pmid:1721460
Deguchi K et al. Effects of FK 506 on acute experimental allergic encephalomyelitis. 1991 Transplant. Proc. pmid:1721461
Bolton C The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. 1991 Transplant. Proc. pmid:1721462
McManus BM et al. Impact of FK 506 on myocarditis in the enteroviral murine model. 1991 Transplant. Proc. pmid:1721463
Nossal GJ Summary of the First International FK 506 Congress: perspectives and prospects. 1991 Transplant. Proc. pmid:1721464
Brizuela L et al. Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. 1991 Mol. Cell. Biol. pmid:1715022
Heitman J et al. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. 1991 Science pmid:1715094
Morris RE Rapamycin: FK506's fraternal twin or distant cousin? 1991 Immunol. Today pmid:1715165
Baumann G et al. Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. 1991 New Biol. pmid:1715185
Liu J et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. 1991 Cell pmid:1715244
Henderson DJ et al. Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. 1991 Immunology pmid:1715317
Unmasking immunosuppression. 1991 Lancet pmid:1717800
Ericzon BG et al. Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. 1991 Transplant. Proc. pmid:1703695
Markus PM et al. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. 1991 Transplantation pmid:1718063
Kumano K et al. FK 506-induced nephrotoxicity in rats. 1991 Transplant. Proc. pmid:1703696
Ryu S and Yasunami Y The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. 1991 Transplantation pmid:1718064
Kuroki H et al. Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. 1991 Transplant. Proc. pmid:1703697
Starzl TE et al. Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. 1991 Transplantation pmid:1718068
Morris RE et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. 1991 Transplant. Proc. pmid:1703698
Lane WS et al. Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus. 1991 J. Protein Chem. pmid:1718307
Goto S et al. Effect of FK 506 and cyclosporine on heart allograft survival in rats. 1991 Transplant. Proc. pmid:1703700
James DG Which immunomodulator? 1991 Br J Clin Pract pmid:1718384
Flavin T et al. Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. 1991 Transplant. Proc. pmid:1703701